đź“° Curated Industry Article
This is a summary of a full article from a trusted healthcare and insurance publication. Click “Read Full Article” below to read the complete story.

Oyster Therapeutics’ lead program penetrates the brain to degrade pathological tau associated with Alzheimer’s disease. Eli Lilly, maker of the amyloid-targeting Alzheimer’s drug Kisunla, participated in the startup’s new financing.
The post Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders appeared first on MedCity News.
đź’ˇ What This Means For You
[armfox_dynamic_insight]
ARMFOX HEALTHCARE
Stay Informed. Protect Your Future.
No pressure. No jargon. Just honest answers from advisors who genuinely care about your family’s protection.
đź“° This article is sourced from a trusted healthcare and insurance industry publication. Armfox Healthcare shares this for informational purposes only. Always consult a licensed advisor for personalized guidance.